The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).
 
Jean-Pierre Delord
No Relationships to Disclose
 
Antoine Hollebecque
Consulting or Advisory Role - Amgen; Merck Serono
 
J. P. De Boer
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Eisai; Merck; MSD
Research Funding - Merck
 
Jacques De Greve
Travel, Accommodations, Expenses - Boehringer Ingelheim; Roche
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - Boehringer Ingelheim; Debiopharm Group; Merck Sharp & Dohme; Nanobiotix; Pfizer
Research Funding - Bayer; Janssen; Novartis; Sanofi
 
Rom S. Leidner
Research Funding - Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Robert L. Ferris
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; Merck; Pfizer
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; VentiRx
 
Shangbang Rao
No Relationships to Disclose
 
Ibrahima Soumaoro
Employment - Bristol-Myers Squibb
 
Z. Alexander Cao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Hyunseok Kang
Research Funding - Advaxis; AstraZeneca; Bristol-Myers Squibb; ImmunoGen; Merck; Novartis; Plexxikon; VentiRx
 
Suzanne Louise Topalian
Stock and Other Ownership Interests - Aduro Biotech (I); Compugen (I); Five Prime Therapeutics; Jounce Therapeutics (I); NexImmune (I); Potenza Therapeutics (I)
Consulting or Advisory Role - Amgen (I); Five Prime Therapeutics; GlaxoSmithKline; Inanovate; Jounce Therapeutics; MedImmune (I); Merck (I); Pfizer (I); Potenza Therapeutics (I); Sanofi (I)
Research Funding - Bristol-Myers Squibb; Compugen (I); Potenza Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Aduro Biotech (I); Bristol-Myers Squibb (I); Potenza Therapeutics (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Five Prime Therapeutics